Loading...

Daily news and top headlines for life science research professionals

FREE Email Newsletter View Sample


Equity Brief: Ratings Changes for November 6th: SCOR, SIAL, SLTM, SREV, STX, TDC, TESO, TEVA, TJX

By The Associated Press Tuesday, November 6, 2023

See today's top life science stories and headlines - Sign up now!

newsvine diigo google
slashdot
Share
Loading...

A number of stocks were upgraded and downgraded by equities research analysts today, as reported by Analyst Ratings Network (http://bit.ly/equitybriefdaily) and Equity Brief:

Oppenheimer reiterated its outperform rating on shares of COMSCORE, Inc. (SCOR).

KeyBanc upgraded shares of Sigma-Aldrich Corp (SIAL) from a hold rating to a buy rating. KeyBanc now has a $88.00 price target on the stock.

Ascendiant Capital Markets upgraded shares of Solta Medical Inc. (SLTM) from a buy rating to a strong-buy rating. Ascendiant Capital Markets now has a $3.75 price target on the stock. They wrote, "Revenue was $35.0 MM (+28%), compared to the consensus estimate of $33.9 MM, in what is seasonally the slowest quarter of the year. GAAP EPS was ($0.04) compared to consensus EPS of ($0.03). Non-GAAP adjusted EPS was $0.03. . In our opinion, the recent weakness in the stock has created an attractive entry point. Hence, we are upgrading our rating to Strong Buy. Our 12-month price target of $3.75 represents a target forward EV/EBITDAS multiple of 12.3x our 2013 estimate."

Deutsche Bank downgraded shares of Servicesource Intern (SREV) from a buy rating to a hold rating. They wrote, "4Q guide was reduced by $9m due to 3 key factors - reduced engagements at customers/customer losses ($5.5m), timing of ACV conversion getting pushed out ($1.5m), and higher back end weighting of new ACV ($2m). The company disclosed loss of a platform-based technology customer, which we believe had a $5m - $6m annual revenue run-rate. Meanwhile, other technology customers cut back on spend as they saw core business slow. Meanwhile the company reiterates pipeline is up 60% y/y, but lower expected ACV growth (15% - 17%) indicates tougher conversion rates. We believe Renew OnDemand is off to a good start (16 customer engagements, including Qualcomm), but anticipate longer time to maturity and do not see this improving margins in near-term."

Morgan Stanley downgraded shares of Servicesource Intern (SREV) from an overweight rating to an equal weight rating.

Credit Agricole downgraded shares of Servicesource Intern (SREV) from a buy rating to an outperform rating.

Zacks reiterated its neutral rating on shares of Seagate (STX). They have a $29.00 price target on the stock. Zacks' analyst wrote, "Ace disk drive-maker Seagate reported a modest first quarter 2013, with revenue improving substantially but EPS missing our expectation. Seagate's position in the HDD vertical is impressive and full recovery in the HDD industry and increasing demand will solidify the current position. Also, Seagate's strong foothold in the Enterprise SSD market will help it to generate healthy revenue growth in fiscal 2013 and beyond, which in turn will improve its margins. While the current uncertainty in the PC market (to which Seagate is highly exposed), Euro concerns and competitive offerings from rivals will remain an overhang. We maintain our Neutral recommendation and a target price of $29.00."

Zacks reiterated its neutral rating on shares of Teradata Co. (TDC). They have a $66.00 price target on the stock. Zacks' analyst wrote, "Teradata reported third quarter earnings of $0.65, which beat the Zacks Consensus Estimate by $0.02. The quarter's earnings were positively impacted by higher revenue and margin expansions. Though the top line increased year over year, yet it fell shy of the consensus mark of $667.0 million. We believe that new customer wins and strengthening relationships with large vendors will be the primary revenue drivers as well as increase profits going forward. Moreover, Teradata will continue to benefit from its international expansion, improved traction from sales force expansion, new products and alliances, market share gains and a growing database analytics market. However, increased investment in sales and an increase in the number of competing products from big names including Oracle are resulting in continued pricing pressure. This eventually may limit margin expansion going forward. Thus, we have a Neutral recommendation on the stock with a price target of $66.00."

FBR Capital upgraded shares of Tesco Co. (TESO) from a market perform rating to an outperform rating. FBR Capital now has a $12.00 price target on the stock, up previously from $10.00.

Zacks reiterated its neutral rating on shares of Teva Pharmaceutical Industries Ltd (TEVA). They have a $44.00 price target on the stock. Zacks' analyst wrote, "Teva's third quarter earnings of $1.28 per ADS were 3 cents above the Zacks Consensus Estimate and 2% above the year-ago earnings. Third quarter revenues increased 14% to $5.00 billion, shy of the Zacks Consensus Estimate of $5.06 billion. Teva narrowed its outlook for 2012 and now expects earnings of $5.32 - $5.38 per ADS on total net sales of $20.1 - $20.7 billion. Earlier, the company was expecting earnings of $5.30 - $5.40 per ADS on total net sales of $20 - $21 billion in 2012. We expect EU sales to remain weak throughout the year. Longer-term, the Cephalon acquisition should help Teva expand and strengthen its branded and specialty pharma business. Moreover, the favorable Copaxone ruling is a major win for the company and should do away with any concerns regarding near-term generic competition for the product. We remain Neutral on the stock. We expect investor focus to remain on the upcoming Investor Day (December 11). "

Credit Suisse initiated coverage on shares of TJX Companies Inc (TJX). They issued a neutral rating on the stock and set a $45.00 price target.

Credit Suisse upgraded shares of Toyota Motor (TM) from a neutral rating to an outperform rating.

Stay on top of analysts' coverage with Analyst Ratings Network's free daily email newsletter that provides a concise list of analysts' upgrades, downgrades and initiations. Register at http://bit.ly/equitybriefdaily

Content and Media Contact: newseditor@equitybrief.net

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein. Source: Equity Brief via Thomson Reuters ONE

HUG#1655500

Join the Discussion
Rate Article: Average 0 out of 5
register or log in to comment on this article!

0 Comments

Add Comment

Text Only 2000 character limit

Page 1 of 1

Research Exchange

Live Cell Analysis of Autophagy

Analysis of autophagosome formation using fluorescent cellular imaging and lentiviral biosensors.

Deconstructing 3D Cell Culture

3D culture models offer the potential to significantly reduce drug failure.

Safety Without Sacrifice

Safety Without Sacrifice

Liquid handling ergonomics and performance considerations

ELNs: The Beating Heart of a Scientist’s World

ELNs: The Beating Heart of a Scientist’s World

As ELNs deliver more benefits to researchers, the cost of changing working practice is outweighed by access to high quality, high context collaboration.

Evaluation of a New Nano-Type UV-Vis Spectrophotometer

Analysis of one- to four-microliter size samples for nucleic acids has become routine in many life science laboratories. However, until now, available instruments require considerable manipulation of the instrument and sample; some require manually recording the data. The user must typically lower and raise the arm manually, then wipe the sample manually from the target after each analysis. And fiberoptics used in some of these instruments are subject to deterioration.

Production of Recombinant Proteins and Monoclonal Antibodies in Hollow Fiber Bioreactors

While well-understood, robust and convenient, classical batch-style 2-D culture on non-porous supports or 3-D suspension culture in other devices are really not very biologically relevant models. Cell culture conditions can affect the quality of the antibody or protein produced.

Selecting Robots for Use in Drug Discovery and Testing

Drug discovery and testing, with their need for speed, repeatability and verification, are ideally suited to benefit from robot automation. It is therefore not surprising that robots have been at the forefront of automation developments in both these areas.

HP Scalable Network Storage Systems for Life Sciences

Life sciences research today is advancing exponentially, each step bringing us closer to the realization of truly personalized medicine–preventive care and treatments designed specifically for each individual. In the near future, PCPGM healthcare researchers expect to be able to use predictive genetic testing to create custom treatment plans for individuals and deliver dramatic improvements over today’s one-size-fits-all approach. But research capabilities are only part of the equation; current storage and operating capacities must also evolve to accommodate ever-expanding amounts of data before the goal of personalized medicine can be realized.

STAY INFORMED: SUBSCRIBE TO

Magazine and E-mail Newsletters

Loading...
Loading...

Free Life Science Industry
Subscriptions

Magazine

wireless week

Newsletters

newsletters

Sign up now



MULTIMEDIA

Video:

Epigenetics

Aug 30

Hank & his clone Circus Hank explain the power of epigenetics, which studies the factors that determine how much or whether some genes are expressed in your body.

Podcasts:

Futures In Biotech 93: Snyder's Omics

May 17

Host: Marc Pelletier Co-Host: Andre Nantel, Ph.D. The technologies that our guest has developed are playing an important role in changing the world, not like the car, the microwave and the cell phone, but as in Drs. Flox, McCoy, and Crusher. Guest: Dr. Michael Snyder We invite...

Top Stories and Headlines
EVERY DAY!

FREE Email Newsletter

Information: